By Tomi Kilgore, MarketWatch , Jaimy Lee
Wall Street analysts largely view the clinical-trial data released by Moderna, however limited, as a positive
Investors in Moderna Inc. (MRNA), the preclinical biotechnology company developing one of the front-running COVID-19 vaccine candidates in the U.S., may be facing a volatile ride through the clinical trial process.
Shares of Moderna closed at a record high of $80.00 on Monday after the company released a slice of positive interim clinical data from the first phase of its COVID-19 vaccine trial. That night it announced it would sell $1.34 billion in stock to help fund manufacturing costs associated with the experimental COVID-19 vaccine. The stock took a nose dive on Tuesday, closing at $71.67, likely due in some degree to a Stat News story () that questioned a lack of clinical clarity in the data it provided to investors.
The company's stock was up 3.8% in trading on Wednesday. Year-to-date, it has soared 270.2%, even though the company has no approved products. In 2019, it had $60 million in revenue that came from collaborations and grants.
"Moderna's shares tumbled in late trading following Monday's surge to a fresh new all-time high, as some experts questioned the significance of the firm's successful vaccine trial that sent the major indices soaring as well yesterday," Gorilla Trades strategist Ken Berman wrote Tuesday. "The fact that the company announced a stock offering yesterday also weighed on Moderna's shares, but MRNA is still trading 300% higher on a year-to-date basis, despite today's dip."
Read: Moderna's stock closes at record high after 'compelling' early data for its coronavirus vaccine candidate ()
In a clinical-trial data disclosure on Monday, Moderna shared that eight out of 45 participants in its COVID-19 vaccine study developed neutralizing antibodies, a decision that Stat's Helen Branswell described as a "reason for caution." It didn't share information about the immune response to the experimental vaccine in the remaining 37 participants.
Moderna, however, said that the full data from the trial will be published by the National Institute for Allergy and Infectious Diseases (NIAID), its sponsor for the study. The company had also already disclosed that the Food and Drug Administration (FDA) has given the go-ahead for the company to proceed with the second phase of the clinical trial for its mRNA vaccine candidate, set to begin before the end of June.
Despite the critics cited in the Stat News article, Wall Street analysts largely view the clinical-trial data released by Moderna, however limited, as a positive.
"While samples are not yet available for remaining participants, and we lack specifics on the exact levels of binding antibodies, we view this data as demonstrative of early signs of efficacy," Goldman Sachs analysts wrote in an investor note on Monday.
See also:Dow stumbles 390 points lower to end down sharply as report throws cold water on Moderna's coronavirus vaccine candidate ()
Medical experts and analysts have also raised questions about the lack of complete data from Gilead Sciences Inc.'s (GILD) late-stage study for remdesivir, which was also conducted with the NIAID.) So far, only the topline results from that trial have been shared publicly, though that was enough to inform the emergency use authorization () granted by the FDA earlier this month, at least according to the FDA's letter announcing the EUA.
"We need to see all that data, the publication," Dr. Eric Topol, a cardiologist and director of the Scripps Research Translational Institute, said by email on May 1. "But I do believe the drug has efficacy based on what we now know, it's just not that potent."
Beyond lingering questions about access to the complete Phase 1 clinical trial data set for the investigational vaccine, Moderna's splashy offering on Monday night aiming to sell about $1.3 billion in stock may also have contributed to the dive on Tuesday.
The company disclosed late Tuesday that Chief Executive Stéphane Bancel and Chief Financial Officer Lorence Kim sold stock recently, with Monday's stock price surge following the announcement of early data on its vaccine candidate potentially adding $4 million to Kim's coffers.
See also: AstraZeneca made a bet on Moderna back in 2013. Here's what it's worth now ()
On Friday, Bancel sold 11,046 shares at a weighted average price of $65.56 for about $724,200, as part of a predetermined trading plan adopted Dec. 28, 2018, according to a Form 4 filing () with the Securities and Exchange Commission. He also disposed of 1,577 shares as part of a "bona fide" gift.
Also, on Friday, Kim sold 20,000 shares at a weighted average price of $65.53 for about $1.31 million, as part of a predetermined trading plan (). On Monday, he exercised options to buy 241,000 shares at a weighted average price of $12.45 for about $3.00 million, also as part of a predetermined plan. At the same time, Kim executed sales of 241,000 shares, at a weighted average price of $82.12 for about $19.79 million. That means Kim netted about $16.79 million on the simultaneous buy and sale of shares.
If Kim had executed Monday's trades on Friday, before the coronavirus vaccine-related stock rally, he might have netted $12.79 million, or about $4 million less.
Morgan Stanley analysts on Wednesday set a price target of $90.00 for Moderna, noting that they expect the company will sell estimated 1.5 billion doses during the pandemic and about 150 million doses each year after that. "We are positive on the early data," they wrote.
Moderna's market capitalization is roughly $27.4 billion, up from about $6.4 billion on Jan. 2.
The S&P 500 is down 9.3% year-to-date.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
May 21, 2020 06:08 ET (10:08 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.